VYGR

Over the past six months, Voyager Therapeutics' stock has been impacted by several events. Q2 2026 financial results reported revenue of $3.17 million, falling below analysts' expectations and showing decreased collaboration revenue, which negatively impacted the stock despite beating EPS estimates. At the Wells Fargo 21st Annual Healthcare Conference, the CEO stated that the VY7523 anti-tau antibody program would be terminated if its Q4 2026 tau PET imaging data did not meet a competitive benchmark, introducing significant risk. On July 13, 2026, VY1706 toxicology study results demonstrated that a single intravenous dose was well tolerated and reduced tau, with a clinical trial expected in the second half of 2026, yet this news resulted in a -5.81% negative stock impact. The Q1 2026 earnings report showed a loss and missed revenue estimates. Additionally, CEO Alfred Sandrock sold 11,511 shares of the company's stock on April 2, 2026. Overall, the stock price has lost approximately 20% since May 31, 2026, and declined by 42.68% between September 29, 2025, and September 28, 2026. The company also presented at various investor conferences, including Wells Fargo, HCW @ Home, and H.C. Wainwright.